Triple

T22452719
Position Surface form Disambiguated ID Type / Status
Subject Regulation (EC) No 141/2000 E555033 entity
Predicate shortName P43 FINISHED
Object EU Orphan Regulation NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: EU Orphan Regulation | Statement: [Regulation (EC) No 141/2000, shortName, EU Orphan Regulation]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: EU Orphan Regulation
Context triple: [Regulation (EC) No 141/2000, shortName, EU Orphan Regulation]
  • A. Regulation (EC) No 141/2000 on orphan medicinal products chosen
    Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.
  • B. Community register of orphan medicinal products
    The Community register of orphan medicinal products is the official European Union list of medicines designated for the diagnosis, prevention, or treatment of rare diseases, maintained under the EU’s orphan drug framework.
  • C. European Union pharmaceutical legislation
    European Union pharmaceutical legislation is the body of EU laws and regulations that governs the authorization, supervision, safety, and quality of medicines for human and veterinary use across member states.
  • D. Orphan Drug Act of 1983
    The Orphan Drug Act of 1983 is a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity, tax credits, and research grants to drug manufacturers.
  • E. Committee for Orphan Medicinal Products
    The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e11e5113208190ab58c6b595f9d1d0 completed April 16, 2026, 5:37 p.m.
NER Named-entity recognition batch_69f15b4c63e88190aeedc326599edd18 completed April 29, 2026, 1:13 a.m.
Created at: April 16, 2026, 8:48 p.m.